Deferasirox: the new oral iron chelator.
Indian Pediatr
;
2007 Aug; 44(8): 603-7
Artículo
en Inglés
| IMSEAR
| ID: sea-12387
ABSTRACT
Deferasirox is a new tridentate oral iron chelator developed by computer remodeling recently approved by FDA for children above 2 years. Phase II/III trials have demonstrated similar efficacy to desferrioxamine and better chelation efficiency. Adverse events were minor and growth remained unaffected. Data on cardiac iron chelation is limited although some studies have shown it comparable to deferiprone. The benefit to risk profile of deferasirox is favorable. This promising new drug might decrease the burden of subcutaneous or intravenous infusion improving compliance and hence the life expectation in thalassemic patients.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Idioma:
Inglés
Revista:
Indian Pediatr
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS